Bon Natural Life Limited BON
Annual
Quarterly
FY2025 · ended Sep 30, 2025 · Revenue $18.67M, -21.7% YoY · Filed Jan 23, 2026
Bon Natural Life Limited (BON) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. In fiscal 2025, which ended Sep 30, 2025, it reported revenue of $18.7 million and a net loss of $2.0 million. Free cash flow was $134,288. As of Sep 30, 2025 it held $3.8 million in cash and investments and $12.3 million in total debt.
Revenue
$18.67M
-21.7% vs prior year
Net income
$-1.99M
-601.0% vs prior year
Operating cash flow
$141,115
+101.8% vs prior year
Free cash flow
$134,288
+101.7% vs prior year
EPS
$-0.72
-117.4% vs prior year
Dividend per share
None
Shares outstanding
3.97M
-66.2% vs prior year
Net cash
$-8.52M
FY 2025
Operating margin
-8.7%
FY 2025
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- BON (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- Cayman Islands
- Headquarters
- Shaanxi, China
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1816815
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Sep 30, 2025 |
FY 2024 Sep 30, 2024 |
FY 2023 Sep 30, 2023 |
FY 2022 Sep 30, 2022 |
FY 2021 Sep 30, 2021 |
|---|---|---|---|---|---|
| Revenue | $18.7M | $23.8M | $29.5M | $29.9M | $25.5M |
| Operating income | -$1.6M | $1.9M | $5.9M | $6.6M | $5.4M |
| Net income | -$2.0M | $398,172 | $4.6M | $6.2M | $4.6M |
| Diluted EPS | -$0.72 | $4.14 | $124.92 | $7.43 | $0.68 |
| Operating cash flow | $141,115 | -$7.7M | -$616,904 | -$187,121 | $4.1M |
| Free cash flow | $134,288 | -$7.7M | -$678,810 | -$214,816 | $4.0M |
| Total assets | $85.2M | $61.8M | $46.6M | $37.3M | $36.4M |
| Total liabilities | $27.2M | $17.4M | $10.6M | $7.2M | $9.9M |
| Stockholders' equity | $57.6M | $43.9M | $35.5M | $29.6M | $26.0M |
| Cash and investments | $3.8M | $80,466 | $111,364 | $840,861 | $3.6M |
| Total debt | $12.3M | $7.3M | $4.1M | $5.3M | $3.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Sep 23, 2026 | Mar 31, 2026 |
| 6-K | Current report (foreign issuer) | Mar 19, 2026 | Nov 30, 2025 |
| 6-K | Current report (foreign issuer) | Feb 17, 2026 | Feb 17, 2026 |
| 20-F | Annual report (foreign issuer) | Jan 23, 2026 | Sep 30, 2025 |
| 6-K | Current report (foreign issuer) | Dec 10, 2025 | Dec 10, 2025 |
| 6-K | Current report (foreign issuer) | Nov 25, 2025 | Nov 25, 2025 |
All 152 Bon Natural Life Limited SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.